ALEC - Alector, Inc.
| Previous Close | 19.62 |
| Open | 19.81 |
| Bid | 19.83 x 1800 |
| Ask | 19.90 x 1400 |
| Day's Range | 19.70 - 20.09 |
| 52 Week Range | 13.64 - 27.00 |
| Volume | 102,885 |
| Avg. Volume | 404,070 |
| Market Cap | 1.373B |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.93 |
| Earnings Date | Nov 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.67 |
- GlobeNewswire
Alector to Host R&D Day on December 13, 2019
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2019 -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that it will.
- GlobeNewswire
Alector to Present at the Jefferies 2019 London Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney,.
- GlobeNewswire
Alector Reports Recent Business Highlights and Third Quarter 2019 Financial Results
Initiated AL001 Phase 2 clinical study and dosed multiple frontotemporal dementia patients with a progranulin mutation (FTD-GRN) or a C9orf72 mutation (FTD-C9orf72)Initiated.
- Zacks
4 Biotech Stocks That Could Keep Beating Wall Street
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Alector, Inc. (ALEC)
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]
- Zacks
AC Immune to Earn Milestone From Lilly for Alzheimer's Drug
AC Immune (ACIU) will gain a milestone payment of CHF30 million from partner Eli Lilly for the initiation of the phase I study of ACI-3024, currently being developed to treat Alzheimer's disease.
- Zacks
6 Small Drug Stocks in Focus Ahead of World Alzheimer's Day
Here we discuss six small-cap companies with promising candidates in their pipeline for Alzheimer's disease.
- Simply Wall St.
Alector, Inc.'s (NASDAQ:ALEC) Single Biggest Risk For Investors
As the US$1.3b market cap Alector, Inc. (NASDAQ:ALEC) released another year of negative earnings, investors may be on...
- GlobeNewswire
Alector Initiates Phase 2 Trial of AL001 in Patients with Frontotemporal Dementia
Alector, Inc. (ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced the initiation of patient screening and enrollment for the INFRONT Phase 2 clinical trial for its product candidate AL001. AL001 is being evaluated for the treatment of people with frontotemporal dementia (FTD) with specific genetic mutations, including the granulin gene (FTD-GRN). “We are encouraged by the recent data from our Phase 1b trial of AL001, in which AL001 was well-tolerated and restored progranulin back to normal physiological levels in the central nervous system of FTD-GRN patients,” said Robert Paul, M.D, Ph.D., chief medical officer of Alector.
- GlobeNewswire
Alector to Present at 17th Annual Morgan Stanley Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2019 -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that Arnon.
- GlobeNewswire
Alector Reports Recent Business Highlights and Second Quarter 2019 Financial Results
- Completed planned enrollment of AL001 Phase 1b trial and demonstrated proof-of-mechanism in Frontotemporal Dementia patients - AL101 granted Orphan Drug Designation from.
- GlobeNewswire
Alector Announces the Addition of Kristine Yaffe, M.D., to the Board of Directors
Alector, Inc. (ALEC) today announced the addition of Kristine Yaffe, M.D., to the Company’s board of directors. Dr. Yaffe is the Scola Endowed Chair and Vice Chair, professor of psychiatry, neurology and epidemiology and the director of the Center for Population Brain Health at the University of California, San Francisco (UCSF). “Kristine is an internationally recognized expert in the field of cognitive aging, neurodegeneration and dementia,” said Arnon Rosenthal, Ph.D., chief executive officer of Alector.
- Zacks
AC Immune Initiates Phase I Study for Alzheimer's Disease
AC Immune (ACIU) initiates phase I study of ACI-3024, a Tau Morphomer inhibitor, for the treatment of neurodegenerative diseases like Alzheimer's disease.
- GlobeNewswire
Alector Announces Data from On-going Phase 1b Trial Demonstrating that AL001 Reverses Progranulin Deficiency in Frontotemporal Dementia Patients
Alector, Inc. (ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today reported initial positive data from a subset of patients in the company’s INFRONT clinical study of its product candidate, AL001. AL001 is being evaluated for the treatment of patients with frontotemporal dementia with a granulin mutation (FTD-GRN).
- GlobeNewswire
Alector Announces Upcoming Presentations at 2019 Alzheimer's Association International Conference
SOUTH SAN FRANCISCO, Calif., July 11, 2019 -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for.
- Investor's Business Daily
Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures
Alzheimer's treatment continues to confound biotech companies in the wake of Biogen and Eisai's decision to terminate two late-stage tests. But scientists say there's hope in new theories.
- Associated Press
Alector: 1Q Earnings Snapshot
On a per-share basis, the South San Francisco, California-based company said it had a loss of 42 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed ...
- GlobeNewswire
Alector Reports Recent Business Highlights and First Quarter 2019 Financial Results
In April 2019, Alector dosed the first frontotemporal dementia patient in the Phase 1b portion of the INFRONT clinical study of AL001. In addition to safety, the study will also measure the levels of a critical target specific biomarker, progranulin, in plasma and in cerebrospinal fluid (CSF) to demonstrate proof of mechanism in patients.
- GlobeNewswire
Alector to Present at the Bank of America Merrill Lynch Healthcare Conference on May 15, 2019
SOUTH SAN FRANCISCO, Calif., May 08, 2019 -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for.
- Simply Wall St.
What Percentage Of Alector, Inc. (NASDAQ:ALEC) Shares Do Insiders Own?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Every investor in Alector, Inc. (NASDAQ:ALEC) should be aware of the most powerful shareholder groups...
- GlobeNewswire
Alector Announces First Alzheimer’s Disease Patient Dosed in Phase 1b Study of AL002
Alector, Inc. (ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced dosing of the first Alzheimer’s disease patient in the Phase 1b portion of the INVOKE clinical study of AL002. AL002 is a monoclonal antibody that enhances the activity of TREM2 and is being developed by Alector for the treatment of Alzheimer’s disease in collaboration with its partner AbbVie.
